The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Clinuvel Pharmaceuticals is in advanced discussions with the ...

The European Centre for Disease Prevention and Control (ECDC) said consumption of antibiotics in the EU had increased by one ...

Vir Biotechnology (VIR) “announced that the European Medicines Agency Committee for Orphan Medicinal Products, has issued a positive opinion on ...

The global consumption of antibiotics in Portugal increased by 2% between 2019-2023, double the average increase of 1% in ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for ...

More than 9million prescriptions for Ozempic and similar weight loss drugs are written every year in the US, estimates ...